



OS-10-02

DOCL909 GAU 1644

Express Mail No.: EL 477 036 095 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Application of: Korngold and Huang

MAY 15 2002

Application No.: 09/206,786

Group Art Unit: 1644

TECH CENTER 1600/2900

Filed: December 7, 1998

Examiner: A. DeCloux

For: CD-4 DERIVED PEPTIDES THAT
INHIBIT IMMUNE RESPONSES

Attorney Docket No.: 8666-007

18/E
Jm
5/21/02REPLY WITH AMENDMENTAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Communication from the Examiner mailed April 9, 2002, please enter the following amendment and consider the remarks below in connection with the above-identified patent application. Attached hereto as Exhibit A is a marked-up version of the claims indicating the amendments made herein.

IN THE CLAIMS

Please amend claim 4 to recite as follows:

E 1
4 (twice amended). The peptide of claim 3, which is CNSNQIC (SEQ ID
NO:45).

REMARKS

Claims 4 has been amended to correct the recitation of the sequence identifier number. Claim 4 now recites the peptide of claim 3, which is CNSNQIC (SEQ ID NO:45). The Examiner stated in the Communication that although Applicants had elected the cyclic peptide CNSNQIC as the elected species, it was identified as SEQ ID NO:44, which is indicated to be linear in the Sequence Listing. Applicants respectfully submit that in view of the amendment to claim 4, which now recites SEQ ID NO:45 (which is indicated to be cyclic in the Sequence Listing), Applicants have responded to the Examiner's request to clarify.